BERKELEY, CA (UroToday.com) - Naftopidil, which to a certain extent shows an affinity to α1D-adrenoceptor subtype in addition to a high affinity to α1A-adrenoceptor, has been used for the treatment of benign prostatic obstruction and benign prostatic hyperplasia-associated lower urinary tract symptoms, but this agent has been approved only in a few countries, including Japan.
